177Lu‑BetaBart (RV‑01)
Various solid tumors
Phase 1/2aActive
Key Facts
About AtomVie Global Radiopharma
A leading radiopharma CDMO delivering end‑to‑end cGMP manufacturing and supply for next‑generation theranostics.
View full company profileTherapeutic Areas
Other Various solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Guardant Infinity Biomarker Discovery | Guardant Health | Development/Commercial |
| Cytotoxic Oncology Generic | MSN Laboratories | Pre‑clinical |
| APCEDEN® | APAC Biotech | Approved |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| BeiGene Oncology Portfolio | EVA Pharma | Phase 2/3 |
| Bevacizumab Biosimilar | Bio Usawa Biotechnology | Preclinical |
| PRIMO‑TB161‑001 | Primo Biotechnology | Preclinical |